*Alnylam is proud to feature real patients in our advertising. Patients may or may not be on an Alnylam therapy.

The latest news is just a few clicks away

Sign up today and:

Receive relevant communications and content
Continue learning more about PH1 and OXLUMO® (lumasiran).

I am a: (select one)

Medical Professional

Other

*Please select what describes you best

I describe myself as a:

Please select a description

* Please enter your first name

* Please enter your last name

* Please enter your email address

* This email address is already in use

* Please enter your ZIP/postal code

Medical Specialization

* Please select a medical specialization

Professional Designation

* Please select a professional designation

I am a US resident and would like to receive updates from Alnylam Pharmaceuticals.

By clicking submit, I agree to the Alnylam.com Privacy Policy and consent to the processing of my personal data per the terms outlined in the Data Privacy Notification and Consent.

(Optional)

I would like to speak with an Alnylam representative.

email_update

IMPORTANT SAFETY INFORMATION

Adverse Reactions
The most common (≥20%) adverse reaction reported in patients treated with OXLUMO was injection site reaction. Injection site reactions included erythema, swelling, pain, hematoma, pruritus, and discoloration.

Pregnancy and Lactation
No data are available on the use of OXLUMO in pregnant women. No data are available on the presence of OXLUMO in human milk or its effects on breastfed infants or milk production. Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for OXLUMO and any potential adverse effects on the breastfed child from OXLUMO or the underlying maternal condition.

INDICATION

OXLUMO is indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels in children and adults.

For additional information about OXLUMO, please see the full Prescribing Information.